By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Isarna Therapeutics 

Josef-Engert-Strasse 9

Regensburg    D-93053  Germany
Phone: 49-941-9201-30 Fax: 49-941-9201-329


Company News
FDA Awards Isarna Therapeutics Orphan Drug Designation For ISTH0036 To Improve Glaucoma Treatment Outcome 6/10/2015 8:40:30 AM
Isarna Therapeutics Announces Orphan Drug Designation In The European Union For ISTH0036 To Treat Advanced-Stage Glaucoma 5/21/2015 9:30:47 AM
Isarna Therapeutics Presents Positive Preclinical Results Supporting Development Of ISTH0036 For The Treatment Of Glaucoma 5/11/2015 10:59:23 AM
Isarna Therapeutics Initiates First-In-Human Phase I Trial For ISTH0036 To Treat Advanced Glaucoma 4/16/2015 11:00:14 AM
Isarna Therapeutics Unveils New Selective TGF-Beta Antagonist Program Targeting Multiple Indications In Ophthalmology 1/8/2015 11:05:47 AM
Isarna Therapeutics Raises Euro 5.5 Million, Announces Elizabeth Czerepak Joining As CFO/CBO To Lead U.S. Site 4/24/2014 9:55:21 AM
Isarna Therapeutics Enters Into A Strategic Manufacturing Agreement With Sanofi (France) (SAN.PA) 1/9/2014 12:50:53 PM
Isarna Therapeutics And Santaris Pharma A/S Announce License Agreement For The Development Of Next Generation Oligonucleotides To Treat TGF-Beta-Mediated Diseases 1/8/2014 9:52:47 AM
Antisense Pharma Changes Name to Isarna Therapeutics 9/30/2013 9:42:35 AM
ANTISENSE PHARMA GmbH Announces Revised Development Path for Trabedersen 2/26/2013 11:14:38 AM